Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company's common shares (the "Shares") to the Investor at...
2025-02-11 7:41 AM EST
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 12, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation ("MUMS") from the U.S. Food and Drug Administration ("FDA") for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The company...
2024-12-12 7:30 AM EST
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region.Under the agreement, Swanielle, a bespoke healthcare consulting firm, will help identify a pharmaceutical/biotech company or companies in Southeast Asia...
2024-12-02 7:30 AM EST
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 18, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer."We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high...
2024-11-18 7:30 AM EST
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants have an exercise price of US$4.64 per share and will expire 5 years from the...
2024-11-15 4:47 PM EST
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of US$4.64 per share and will expire 5 years from the date...
2024-11-13 6:45 PM EST
Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing
Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") today announced that it has completed a consolidation of its common shares on a 2-to-1 basis (the "Consolidation").The Company has completed the Consolidation in connection with its proposed U.S. initial public offering and application to list on a U.S. national securities exchange. For further details, please refer to the Company's news release dated May 29, 2024.The Company...
2024-10-28 12:28 PM EDT
Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults
Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") announces the enrollment of the first patient in its Phase 2 clinical trial SKNJCT-003 for the treatment of nodular basal cell carcinoma (nBCC).Clinical Trial Design The clinical study, SKNJCT-003, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 60 subjects presenting with nBCC of the skin. The study will...
2024-08-27 8:36 AM EDT
Medicus Pharma Ltd. Submits Updated Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the submission of an updated and complete Phase 2 Investigational New Drug (IND) clinical protocol (SKNJCT-003) to the United States Food and Drug Administration (FDA) to non-invasively treat basal cell carcinoma (BCC) of the skin using micro-needle arrays containing doxorubicin (D-MNA), developed by its wholly owned portfolio company, Skinject,...
2024-07-15 7:30 AM EDT
Medicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - July 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Equity Offering") of 2,922,500 common shares of the Company ("Shares"), at an issuance price of US$2.00 per Share, for aggregate gross proceeds of US$5,845,000. The Company paid US$375,000 of finders' fees in connection with the Equity Offering.The Equity Offering closed into...
2024-07-05 7:30 AM EDT
Medicus Pharma Ltd. Announces Proposed Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - June 26, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Equity Offering") of 2,922,500 common shares of the Company ("Shares"), at an issuance price of US$2.00 per Share, for aggregate gross proceeds of US$5,845,000. The Company expects to pay US$375,000 of finders' fees in connection with the Equity Offering.The closing of the Equity Offering is...
2024-06-26 6:00 PM EDT
Medicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
Toronto, Ontario--(Newsfile Corp. - May 29, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has publicly filed a registration statement on Form F-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its securities in the United States. The proposed offering is for units consisting of common shares and warrants and the Company intends to list its common...
2024-05-29 7:00 AM EDT
Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed the first closing of its previously announced private placement (the "Private Placement") of 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). The Company issued US$5,172,500 aggregate principal amount of Notes in the first closing, which was unbrokered. The Company may issue additional Notes in one or more further closings, with...
2024-05-03 6:00 PM EDT
Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - April 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete the first closing of a private placement (the "Private Placement") of its 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). Approximately US$5,172,500 aggregate principal amount of Notes will be issued at the first closing, which is expected to occur on or about May 1st , 2024, subject to customary closing conditions,...
2024-04-25 3:07 PM EDT
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce the receipt of comments from the U.S Food and Drug Administration (FDA).The clinical non-hold comments from the FDA consider the results of the study exploratory and request the Company to provide data from clinical studies (SKNJCT-001) to support the dose of 100μg and 200μg of micro-array needles containing doxorubicin (D-MNA). FDA has also requested the...
2024-03-21 7:30 AM EDT
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer
Toronto, Ontario--(Newsfile Corp. - March 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the appointment of Erica Monaco as Chief Operating Officer. Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry. She has spent the last decade in the dermatology sector with an extensive track record of building start-up operations, accelerating change, and driving process...
2024-03-05 7:30 AM EST
Medicus Pharma Ltd. Publishes Phase 1 Clinical Study Report Demonstrating Safety & Tolerability in All Participants with Basal Cell Carcinoma
Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce that it has published the abbreviated clinical study report (CSR) from the SKNJCT-001 Phase 1 safety and tolerability study. SKNJCT-001 is an open-label, dose-escalation, placebo-controlled trial to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD), safety and tolerability of dissolvable microneedle arrays loaded with the...
2024-02-15 7:30 AM EST
Medicus Pharma Ltd. Announces the Filing of a Final Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - January 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") has filed a final short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The Shelf Prospectus allows Medicus to offer from time to time over a 25-month period up to US$50 million (or the equivalent in other currencies) of common shares, preferred shares, warrants, subscription...
2024-01-25 5:30 PM EST
Medicus Pharma Ltd. Announces Listing on Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - January 18, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the listing of its common shares on the Frankfurt Stock Exchange under identification number (WKN) "A3ES6P" and ticker symbol "N46". The Company's common shares continue to be listed on the TSX Venture Exchange under the symbol "MDCX".For further information contact:Carolyn Bonner, President(610) 636-0184cbonner@medicuspharma.com LHA Investor...
2024-01-18 7:55 AM EST
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - January 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce the submission to the United States Food and Drug Administration (FDA) a Phase 2 Investigational New Drug (IND) clinical protocol (SKNJCT-003) to non-invasively treat basal cell Carcinoma (BCC) of the skin using micro-array needles containing doxorubicin (D-MNA), developed by its wholly-owned portfolio company, SkinJect, Inc. The company is seeking...
2024-01-03 7:30 AM EST